MedTrace Logo

Mapracorat Ophthalmic Formulation in Subjects With Allergic Conjunctivitis

NCT01289431 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 236

Last updated 2020-09-04

Study results available
· View outcomes & findings →

Summary

The objective of this study is to evaluate the dose response, and efficacy of Mapracorat ophthalmic formulation compared to its vehicle for the prevention of symptoms and signs associated with allergic conjunctivitis using a conjunctival allergen challenge (CAC) model.

Conditions

  • Conjunctivitis, Allergic

Interventions

DRUG

Mapracorat

administered daily to each eye for 2 weeks following allergen challenge using a CAC model

DRUG

Vehicle

administered daily to each eye for 2 weeks following allergen challenge using a CAC model

Sponsors & Collaborators

  • Bausch & Lomb Incorporated

    lead INDUSTRY

Principal Investigators

  • Rabia Ozden, OD · Bausch & Lomb Incorporated

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2011-04-30
Completion
2011-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01289431 on ClinicalTrials.gov